A citation-based method for searching scientific literature

John R Teerlink, G Michael Felker, John J V McMurray, Scott D Solomon, Kirkwood F Adams, John G F Cleland, Justin A Ezekowitz, Assen Goudev, Peter Macdonald, Marco Metra, Veselin Mitrovic, Piotr Ponikowski, Pranas Serpytis, Jindrich Spinar, János Tomcsányi, Hans J Vandekerckhove, Adriaan A Voors, Maria Laura Monsalvo, James Johnston, Fady I Malik, Narimon Honarpour. Lancet 2016
Times Cited: 161







List of co-cited articles
770 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
John R Teerlink, Rafael Diaz, G Michael Felker, John J V McMurray, Marco Metra, Scott D Solomon, Kirkwood F Adams, Inder Anand, Alexandra Arias-Mendoza, Tor Biering-Sørensen,[...]. N Engl J Med 2021
184
55

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.
Fady I Malik, James J Hartman, Kathleen A Elias, Bradley P Morgan, Hector Rodriguez, Katjusa Brejc, Robert L Anderson, Sandra H Sueoka, Kenneth H Lee, Jeffrey T Finer,[...]. Science 2011
356
52

Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.
John R Teerlink, G Michael Felker, John J V McMurray, Piotr Ponikowski, Marco Metra, Gerasimos S Filippatos, Justin A Ezekowitz, Kenneth Dickstein, John G F Cleland, Jae B Kim,[...]. J Am Coll Cardiol 2016
135
40

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.
John R Teerlink, Cyril P Clarke, Khalil G Saikali, Jacqueline H Lee, Michael M Chen, Rafael D Escandon, Lyndsey Elliott, Rachel Bee, Mohammad Reza Habibzadeh, Jonathan H Goldman,[...]. Lancet 2011
178
40

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
38

Angiotensin-neprilysin inhibition versus enalapril in heart failure.
John J V McMurray, Milton Packer, Akshay S Desai, Jianjian Gong, Martin P Lefkowitz, Adel R Rizkala, Jean L Rouleau, Victor C Shi, Scott D Solomon, Karl Swedberg,[...]. N Engl J Med 2014
36

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
33

Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF.
John R Teerlink, Rafael Diaz, G Michael Felker, John J V McMurray, Marco Metra, Scott D Solomon, Jason C Legg, Gustavo Büchele, Claire Varin, Christopher E Kurtz,[...]. JACC Heart Fail 2020
66
48

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.
John G F Cleland, John R Teerlink, Roxy Senior, Evgeny M Nifontov, John J V Mc Murray, Chim C Lang, Vitaly A Tsyrlin, Barry H Greenberg, Jamil Mayet, Darrel P Francis,[...]. Lancet 2011
226
31

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Paul W Armstrong, Burkert Pieske, Kevin J Anstrom, Justin Ezekowitz, Adrian F Hernandez, Javed Butler, Carolyn S P Lam, Piotr Ponikowski, Adriaan A Voors, Gang Jia,[...]. N Engl J Med 2020
339
31

Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Eric J Velazquez, David A Morrow, Adam D DeVore, Carol I Duffy, Andrew P Ambrosy, Kevin McCague, Ricardo Rocha, Eugene Braunwald. N Engl J Med 2019
472
26

Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil.
Vicente J Planelles-Herrero, James J Hartman, Julien Robert-Paganin, Fady I Malik, Anne Houdusse. Nat Commun 2017
93
26

Cardiac Calcitropes, Myotropes, and Mitotropes: JACC Review Topic of the Week.
Mitchell A Psotka, Stephen S Gottlieb, Gary S Francis, Larry A Allen, John R Teerlink, Kirkwood F Adams, Giuseppe M C Rosano, Patrizio Lancellotti. J Am Coll Cardiol 2019
58
39


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
19

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Karl Swedberg, Michel Komajda, Michael Böhm, Jeffrey S Borer, Ian Ford, Ariane Dubost-Brama, Guy Lerebours, Luigi Tavazzi. Lancet 2010
18

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska,[...]. Eur Heart J 2016
18

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Deepak L Bhatt, Michael Szarek, P Gabriel Steg, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra,[...]. N Engl J Med 2021
449
18

Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
Mihai Gheorghiade, Stephen J Greene, Javed Butler, Gerasimos Filippatos, Carolyn S P Lam, Aldo P Maggioni, Piotr Ponikowski, Sanjiv J Shah, Scott D Solomon, Elisabeth Kraigher-Krainer,[...]. JAMA 2015
191
17


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
16

Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure.
You-Tang Shen, Fady I Malik, Xin Zhao, Christophe Depre, Sunil K Dhar, Patricio Abarzúa, David J Morgans, Stephen F Vatner. Circ Heart Fail 2010
112
16

Eplerenone in patients with systolic heart failure and mild symptoms.
Faiez Zannad, John J V McMurray, Henry Krum, Dirk J van Veldhuisen, Karl Swedberg, Harry Shi, John Vincent, Stuart J Pocock, Bertram Pitt. N Engl J Med 2011
16

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Faiez Zannad, João Pedro Ferreira, Stuart J Pocock, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Martina Brueckmann, Anne Pernille Ofstad, Egon Pfarr, Waheed Jamal,[...]. Lancet 2020
394
16

Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF.
John R Teerlink, Rafael Diaz, G Michael Felker, John J V McMurray, Marco Metra, Scott D Solomon, Tor Biering-Sørensen, Michael Böhm, Diana Bonderman, James C Fang,[...]. J Am Coll Cardiol 2021
23
65

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
14

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
Salim Yusuf, Bertram Pitt, Clarence E Davis, William B Hood, Jay N Cohn. N Engl J Med 1991
14

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Theresa A McDonagh, Marco Metra, Marianna Adamo, Roy S Gardner, Andreas Baumbach, Michael Böhm, Haran Burri, Javed Butler, Jelena Čelutkienė, Ovidiu Chioncel,[...]. Eur Heart J 2021
955
14

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
Christopher B Granger, John J V McMurray, Salim Yusuf, Peter Held, Eric L Michelson, Bertil Olofsson, Jan Ostergren, Marc A Pfeffer, Karl Swedberg. Lancet 2003
13

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Scott D Solomon, John J V McMurray, Inder S Anand, Junbo Ge, Carolyn S P Lam, Aldo P Maggioni, Felipe Martinez, Milton Packer, Marc A Pfeffer, Burkert Pieske,[...]. N Engl J Med 2019
759
13

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska,[...]. Eur J Heart Fail 2016
12

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
12

Omecamtiv Mecarbil Enhances the Duty Ratio of Human β-Cardiac Myosin Resulting in Increased Calcium Sensitivity and Slowed Force Development in Cardiac Muscle.
Anja M Swenson, Wanjian Tang, Cheavar A Blair, Christopher M Fetrow, William C Unrath, Michael J Previs, Kenneth S Campbell, Christopher M Yengo. J Biol Chem 2017
47
25

Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke.
Michael S Woody, Michael J Greenberg, Bipasha Barua, Donald A Winkelmann, Yale E Goldman, E Michael Ostap. Nat Commun 2018
57
21

Effect of carvedilol on survival in severe chronic heart failure.
M Packer, A J Coats, M B Fowler, H A Katus, H Krum, P Mohacsi, J L Rouleau, M Tendera, A Castaigne, E B Roecker,[...]. N Engl J Med 2001
12

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials.
John R Teerlink, Rafael Diaz, G Michael Felker, John J V McMurray, Marco Metra, Scott D Solomon, Kirkwood F Adams, Inder Anand, Alexandra Arias-Mendoza, Tor Biering-Sørensen,[...]. Eur J Heart Fail 2020
28
42

Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil.
Edgardo Kaplinsky, Gordon Mallarkey. Drugs Context 2018
31
35

Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects.
Rameshraja Palaparthy, Christopher Banfield, Paco Alvarez, Lucy Yan, Brian Smith, Jessica Johnson, Maria Laura Monsalvo, Fady Malik. Int J Clin Pharmacol Ther 2016
25
44

Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers.
Robert L Anderson, Darshan V Trivedi, Saswata S Sarkar, Marcus Henze, Weikang Ma, Henry Gong, Christopher S Rogers, Joshua M Gorham, Fiona L Wong, Makenna M Morck,[...]. Proc Natl Acad Sci U S A 2018
117
11

Omecamtiv Mecarbil modulates the kinetic and motile properties of porcine β-cardiac myosin.
Yingying Liu, Howard D White, Betty Belknap, Donald A Winkelmann, Eva Forgacs. Biochemistry 2015
72
15

A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice.
Eric M Green, Hiroko Wakimoto, Robert L Anderson, Marc J Evanchik, Joshua M Gorham, Brooke C Harrison, Marcus Henze, Raja Kawas, Johan D Oslob, Hector M Rodriguez,[...]. Science 2016
279
11

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Iacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa, Theodore P Abraham, Ahmad Masri, Pablo Garcia-Pavia, Sara Saberi, Neal K Lakdawala, Matthew T Wheeler, Anjali Owens,[...]. Lancet 2020
153
11

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
947
11

Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.
James L Januzzi, Margaret F Prescott, Javed Butler, G Michael Felker, Alan S Maisel, Kevin McCague, Alexander Camacho, Ileana L Piña, Ricardo A Rocha, Amil M Shah,[...]. JAMA 2019
214
11

Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology.
Petar M Seferovic, Piotr Ponikowski, Stefan D Anker, Johann Bauersachs, Ovidiu Chioncel, John G F Cleland, Rudolf A de Boer, Heinz Drexel, Tuvia Ben Gal, Loreena Hill,[...]. Eur J Heart Fail 2019
315
11

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.
Clyde W Yancy, Mariell Jessup, Biykem Bozkurt, Javed Butler, Donald E Casey, Monica M Colvin, Mark H Drazner, Gerasimos S Filippatos, Gregg C Fonarow, Michael M Givertz,[...]. Circulation 2017
10


Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.
Bradley P Morgan, Alexander Muci, Pu-Ping Lu, Xiangping Qian, Todd Tochimoto, Whitney W Smith, Marc Garard, Erica Kraynack, Scott Collibee, Ion Suehiro,[...]. ACS Med Chem Lett 2010
70
14




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.